Stockscreener 앱 받기
5.22
1.14%
-0.06
전일 마감가:
$5.28
열려 있는:
$5.2817
하루 거래량:
10,919
Relative Volume:
1.17
시가총액:
$72.52M
수익:
$57.94M
순이익/손실:
$-2.34M
주가수익비율:
-31.33
EPS:
-0.1666
순현금흐름:
$3.82M
1주 성능:
+5.88%
1개월 성능:
-4.22%
6개월 성능:
-13.00%
1년 성능:
-24.51%
1일 변동 폭
$5.06
$5.41
1주일 범위
$4.97
$5.51
52주 변동 폭
$4.83
$8.74
Champions Oncology Inc Stock (CSBR) Company Profile
명칭
Champions Oncology Inc
전화
410-369-0365
주소
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.22 | 71.97M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-12 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2019-11-18 | 개시 | The Benchmark Company | Speculative Buy |
Champions Oncology Inc 주식(CSBR)의 최신 뉴스
Champions (CSBR) Range: Finishes 4.86% Up at $5.18 in the Latest Session; Price Setup: the Near-Term Reference Band Stretches From $4.92 to $5.44 in the Available RecordHidden Order - vinanet.vn
Rest-Of-Asia-Pacific Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Latin-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Comedian Michael Kosta Headlines Karmanos Comedy Champions on New October Date, Hosted by 101 WRIF's Jade Springart - PR Newswire
Precision Trading with Champions Oncology Inc. (CSBR) Risk Zones - Stock Traders Daily
OSTX Stock Price and Chart — AMEX:OSTX - TradingView
Manulife China Bank Life Champions Early Health Action and Financial Planning at The Art of Longevity - Mindanao Times
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer - The ASCO Post
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oil Prices Rise as Iran Draft Plan Proposes Barring U.S. and Israel From Strait of HormuzAnnual Report - Vinanet
Technical Reactions to CSBR Trends in Macro Strategies - Stock Traders Daily
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology (CSBR) Pulls Back 2.7% as Shares Test Support Near $5.33Sweep Order Flow - vinanet.vn
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - theglobeandmail.com
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
AgomAb Therapeutics (AGMB) Holds Steady Near Resistance as Biotech Sector Shows Mixed SentimentHead and Shoulders - vinanet.vn
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Rising costs push Champions Oncology (NASDAQ: CSBR) into 2026 loss - Stock Titan
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026 - TradingView
CSBR: Record revenue and positive adjusted EBITDA achieved, driven by core research services growth - TradingView
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline - TradingView
Champions Oncology Reports Record Annual Revenue of $59 Million - Eagle-Tribune
BRIEF-Champions Oncology Q4 Adjusted EPS USD 0.01 - TradingView
At fiscal year-end, Champions Oncology had $4.9M cash, no debt - Stock Titan
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CSBR|Champions Oncology Inc|Price:6.160|Chg%:+0.030 - TradingKey
Champions Oncology, Inc. Revenue Breakdown – MUN:2I3 - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3 - TradingView
Champions Oncology, Inc. Revenue Breakdown – FWB:2I3 - TradingView
CSBR Q4'25 Earnings: EPS estimate is (0.05) USD - TradingView
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
CSBR Q2 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Revenue Reporting GapsCash Flow Report - vinanet.vn
2 Microcaps With Gross Margin Catalysts - Yahoo Finance
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation - Yahoo! Finance Canada
Champions Oncology (CSBR.US) will release its earnings report after market close on July 27. - Moomoo
Champions Oncology to announce Q4 and FY26 results on July 27 - scanx.trade
Champions Oncology Inc (CSBR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):